In this review we summarize the clinical results obtained on CD33 targeting by GO in AML as single agent and in combination with chemotherapy, its potential benefit pre- and post-transplantation and we discuss the predictive biomarkers of therapy response. This evidence concerns the gene CD33 and acute myeloid leukemia.